Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in …
T Lequerré, P Quartier, D Rosellini, F Alaoui… - Annals of the rheumatic …, 2008 - Elsevier
Background: Anakinra treatment has been reported to be effective in some patients with
systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD).
Objectives: To assess the efficacy and the safety of anakinra treatment in SoJIA and AoSD.
Methods: SoJIA and AoSD patients were treated with anakinra (1–2 mg/kg/day in children,
100 mg/day in adults); we analysed its effect on fever, erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) levels, numbers of swollen and tender joints, the assessment …
systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD).
Objectives: To assess the efficacy and the safety of anakinra treatment in SoJIA and AoSD.
Methods: SoJIA and AoSD patients were treated with anakinra (1–2 mg/kg/day in children,
100 mg/day in adults); we analysed its effect on fever, erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) levels, numbers of swollen and tender joints, the assessment …